Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B
Dania Al Labban, … , Renato Panizzon, G. Paolo Dotto
Dania Al Labban, … , Renato Panizzon, G. Paolo Dotto
Published May 14, 2018
Citation Information: J Clin Invest. 2018;128(6):2581-2599. https://doi.org/10.1172/JCI96915.
View: Text | PDF
Research Article Cell biology Oncology

Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B

  • Text
  • PDF
Abstract

Notch 1/2 genes play tumor-suppressing functions in squamous cell carcinoma (SCC), a very common malignancy in skin and internal organs. In contrast with Notch, we show that the transcription factor CSL (also known as RBP-Jκ), a key effector of canonical Notch signaling endowed with intrinsic transcription-repressive functions, plays a tumor-promoting function in SCC development. Expression of this gene decreased in upper epidermal layers and human keratinocytes (HKCs) undergoing differentiation, while it increased in premalignant and malignant SCC lesions from skin, head/neck, and lung. Increased CSL levels enhanced the proliferative potential of HKCs and SCC cells, while silencing of CSL induced growth arrest and apoptosis. In vivo, SCC cells with increased CSL levels gave rise to rapidly expanding tumors, while cells with silenced CSL formed smaller and more differentiated tumors with enhanced inflammatory infiltrate. Global transcriptomic analysis of HKCs and SCC cells with silenced CSL revealed major modulation of apoptotic, cell-cycle, and proinflammatory genes. We also show that the histone demethylase KDM6B is a direct CSL-negative target, with inverse roles of CSL in HKC and SCC proliferative capacity, tumorigenesis, and tumor-associated inflammatory reaction. CSL/KDM6B protein expression could be used as a biomarker of SCC development and indicator of cancer treatment.

Authors

Dania Al Labban, Seung-Hee Jo, Paola Ostano, Chiara Saglietti, Massimo Bongiovanni, Renato Panizzon, G. Paolo Dotto

×

Figure 2

Higher CSL expression in proliferating vs. differentiating keratinocytes and squamous cancer cells.

Options: View larger image (or click on image) Download as PowerPoint
Higher CSL expression in proliferating vs. differentiating keratinocytes...
(A) Immunoblot analysis of CSL expression in HKCs under proliferating (50% and 70% confluence [cf]) versus differentiating culture conditions (7 days at 100% cf; 48 hours in suspension culture [susp]). Immunoblot was sequentially probed with antibodies against CSL, involucrin (IVL) (80), and actin. Numbers refer to relative folds of CSL expression using actin for normalization. Results of similar experiment with 2 other HKC strains are shown in Supplemental Figure 1D. (B) HKCs as in A were analyzed by RT-qPCR for CSL and involucrin mRNA expression with 36B4 for normalization. Similar analysis of 2 additional HKC strains is shown in Supplemental Figure 1E. (C) Immunoblot analysis of CSL expression in HKCs under proliferating conditions versus panel of skin and oral SCC cell lines. CSL protein on immunoblot can be variously detected as a single or dual band, probably reflecting different phosphorylation states, with no correlation to p53 status of cells. Immunoblot was sequentially probed with antibodies against CSL, actin, and p53. Right panel: quantification of relative levels of CSL expression of this and 2 other immunoblots, using actin for normalization. (D) Cells as in C were analyzed by RT-qPCR for CSL mRNA expression with 36B4 for normalization. (E) Lung SCC cell lines were analyzed in parallel with HBECs for levels of CSL or p53 expression utilizing tubulin as equal loading control. Right panel: quantification of relative levels of CSL expression of this and 2 other immunoblots. (F) Cells as in E were analyzed by RT-qPCR for CSL mRNA expression with 36B4 for normalization. (C–F) Data are shown as mean ± SEM. *P < 0.05; **P < 0.005; ***P < 0.0005, 1-way ANOVA with Dunnett’s test. n = 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts